Addictions are chronic brain diseases that can be treated medically
Opiant is a pharmaceutical company with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.
We are headquartered in Santa Monica, with additional offices in London, UK.
Statistics
Patient population with addictions and drug overdose
Over 20 million people are affected by addictions and drug overdose in the United States.
with emergency room visits with Acute Cannabinoid Overdose
with Alcohol Use Disorder
with Opioid Use Disorder and 48k opioid-related overdose deaths annually
PIPELINE
Our pipeline
In response to a growing public health need, Opiant is developing products to treat addictions and drug overdose.
Spotlight
The latest from Opiant
Fighting the Opioid Crisis – FOX Business
October 21, 2019 – Opiant CEO Roger Crystal on The Claman Countdown discusses the fight on the opioid crisis.
Fighting the Opioid Crisis – Fox Business Network’s “Mornings with Maria”
August 3, 2018 – Opiant CEO Dr. Roger Crystal discusses NARCAN® following singer Demi Lovato’s hospitalization.
Meeting of the President’s Commission on Combating Drug Addiction and Opioid Crisis
September 27, 2017 – Opiant CEO Dr. Roger Crystal testifies before the President’s Commission on Combating Drug Addiction and the Opioid Crisis.
Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
SANTA MONICA, Calif. , March 04, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions…
Opiant Pharmaceuticals to Report Fourth Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, March 4
SANTA MONICA, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions…
Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose
SANTA MONICA, Calif. , Jan. 02, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions…
March 4, 2020 4:30 PM EST : Opiant Pharmaceuticals Fourth Quarter 2019 Financial Results Conference Call
November 12, 2019 4:30 PM EST : Opiant Pharmaceuticals Third Quarter 2019 Financial Results Conference Call
October 17, 2019 12:00 PM EDT : Research & Development Meeting on Emerging Therapeutics for the Treatment of Addiction and Drug Overdose
Cannabinoid1 (CB‐1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose
Published in 2020 by the Journal of Neural Transmission.
Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose
Published in April 2019 by ASPET Journals.
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects
Published in March 2019 by American College of Neuropsychopharmacology.